Psychedelic therapy: a roadmap for wider acceptance and utilization

Mason Marks^{1

2}, I Glenn Cohen^{3

4}

Affiliations

¹ Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, MA, USA. mmarks@law.harvard.edu.
² University of New Hampshire Franklin Pierce School of Law, Concord, NH, USA. mmarks@law.harvard.edu.
³ Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, MA, USA.
⁴ Harvard Law School, Cambridge, MA, USA.

Mason Marks et al. Nat Med. 2021 Oct.

. 2021 Oct;27(10):1669-1671.

doi: 10.1038/s41591-021-01530-3.

Mason Marks^{1

2}, I Glenn Cohen^{3

4}

¹ Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, MA, USA. mmarks@law.harvard.edu.
² University of New Hampshire Franklin Pierce School of Law, Concord, NH, USA. mmarks@law.harvard.edu.
³ Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Cambridge, MA, USA.
⁴ Harvard Law School, Cambridge, MA, USA.

No abstract available

References

1. Marks, M. N. Y. Univ. J. Legis. Public Policy 21, 69–140 (2018).
1. Davis, A. K. et al. JAMA Psychiatry 78, 481–489 (2021). - DOI
1. Mithoefer, M. C. et al. Psychopharmacol. 236, 2735–2745 (2019). - DOI
1. Griffiths, R. R., Johnson, M. W. & Carducci, M. A. J. Psychopharmacol. 30, 1181–1197 (2016). - DOI
1. Johnson, M. W., Griffiths, R. R. & Hendricks, P. S. Neuropharmacol. 142, 143–166 (2018). - DOI